Digitala Vetenskapliga Arkivet

Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
AlphaFold accelerated discovery of psychotropic agonists targeting the trace amine-associated receptor 1
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Cell and Molecular Biology, Computational Biology and Bioinformatics. Uppsala University, Science for Life Laboratory, SciLifeLab.ORCID iD: 0000-0002-3449-5086
Karolinska Inst, Dept Clin Neurosci, Neuro Svenningsson, SE-17176 Stockholm, Sweden..
Uppsala University, Disciplinary Domain of Science and Technology, Biology, Department of Cell and Molecular Biology, Computational Biology and Bioinformatics. Uppsala University, Science for Life Laboratory, SciLifeLab.
Karolinska Inst, Dept Clin Neurosci, Neuro Svenningsson, SE-17176 Stockholm, Sweden.;Univ Cincinnati, James J & Joan A Gardner Family Ctr Parkinsons Dis, Dept Neurol, Cincinnati, OH USA..
Show others and affiliations
2024 (English)In: Science Advances, E-ISSN 2375-2548, Vol. 10, no 32, article id eadn1524Article in journal (Refereed) Published
Abstract [en]

Artificial intelligence is revolutionizing protein structure prediction, providing unprecedented opportunities for drug design. To assess the potential impact on ligand discovery, we compared virtual screens using protein structures generated by the AlphaFold machine learning method and traditional homology modeling. More than 16 million compounds were docked to models of the trace amine-associated receptor 1 (TAAR1), a G protein-coupled receptor of unknown structure and target for treating neuropsychiatric disorders. Sets of 30 and 32 highly ranked compounds from the AlphaFold and homology model screens, respectively, were experimentally evaluated. Of these, 25 were TAAR1 agonists with potencies ranging from 12 to 0.03 mu M. The AlphaFold screen yielded a more than twofold higher hit rate (60%) than the homology model and discovered the most potent agonists. A TAAR1 agonist with a promising selectivity profile and drug-like properties showed physiological and antipsychotic-like effects in wild-type but not in TAAR1 knockout mice. These results demonstrate that AlphaFold structures can accelerate drug discovery.

Place, publisher, year, edition, pages
American Association for the Advancement of Science (AAAS), 2024. Vol. 10, no 32, article id eadn1524
National Category
Pharmacology and Toxicology
Identifiers
URN: urn:nbn:se:uu:diva-536990DOI: 10.1126/sciadv.adn1524ISI: 001285647700011PubMedID: 39110804OAI: oai:DiVA.org:uu-536990DiVA, id: diva2:1896130
Funder
Knut and Alice Wallenberg Foundation, KAW 2019.0130Swedish Research CouncilSwedish Research Council, 2022-06725Swedish Research Council, 2018-05973Available from: 2024-09-09 Created: 2024-09-09 Last updated: 2026-08-27Bibliographically approved
In thesis
1. Computational studies of the evolution, structure, and function of G protein-coupled receptors
Open this publication in new window or tab >>Computational studies of the evolution, structure, and function of G protein-coupled receptors
2026 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

G protein-coupled receptors (GPCRs) are the largest family of membrane proteins in the human genome and the most exploited target class in pharmacology. Structure-based methods use three-dimensional models to investigate ligand recognition, selectivity, and binding affinities. Paper I compares AlphaFold2 (AF2) and homology models for ligand discovery at the trace amine-associated receptor 1 (TAAR1), whose structure was unavailable. Docking 16 million compounds followed by experimental testing gave hit rates of 60% and 22%, respectively, and an optimized hit produced antipsychotic-like effects in mice but not in Taar1-knockout mice. Paper II addresses a limitation of AF2, which tends to capture a narrow range of binding-site conformations. Masking selected columns of the multiple sequence alignment diversifies the predicted ensemble and improves the enrichment achieved by the best-performing models across 10 class A GPCRs. Paper III examines two Saccoglossus kowalevskii receptors with identical binding-site residues but different selectivity. Chimeric receptors, cryo-EM, and simulations identify a residue network outside the binding site that shifts relative ligand preference by >10,000-fold in both functional assays without changing any binding-site residue. Paper IV extends this principle to the human β2-adrenoceptor and D1 receptor, where switching selectivity requires substitutions both within and outside the orthosteric binding site. Paper V benchmarks a free-energy perturbation workflow across 16 protein targets and 639 ligand transformations and shows that focusing the simulation around the binding site reduces computational demand while retaining competitive accuracy. Papers VI and VII apply this protocol within two medicinal chemistry campaigns targeting adenosine receptors, where free energy calculations rationalize the effects of chemical substitutions on affinity and selectivity and distinguish plausible binding modes. Together, these studies show that structure-based GPCR discovery benefits from sampling ligand-compatible receptor conformations, considering how interactions within and beyond the binding site determine selectivity, and applying focused free-energy calculations to quantify affinity changes and distinguish alternative binding modes.

Place, publisher, year, edition, pages
Uppsala: Acta Universitatis Upsaliensis, 2026. p. 97
Series
Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology, ISSN 1651-6214 ; 2710
Keywords
G protein-coupled receptors; aminergic GPCRs; AlphaFold2; ligand selectivity; structure-based virtual screening; molecular dynamics; free energy perturbation; ligand binding affinity
National Category
Bioinformatics and Computational Biology
Identifiers
urn:nbn:se:uu:diva-596619 (URN)978-91-513-2940-6 (ISBN)
Public defence
2026-10-16, A1:111a, Uppsala Biomedicinska Centrum (BMC), Husargatan 3, Uppsala, 13:15 (English)
Opponent
Supervisors
Available from: 2026-09-22 Created: 2026-08-27 Last updated: 2026-09-22

Open Access in DiVA

fulltext(1379 kB)475 downloads
File information
File name FULLTEXT01.pdfFile size 1379 kBChecksum SHA-512
867e051ad8fa218a7651a55d644cdd23969d0ed227eee67429be16fb564ad22e2909d4b0c3777856add4964a2248bf22b65e0ca0e5d12b7b318d334c19b3e273
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Díaz-Holguin, AlejandroVo, Duc Duyde Vaca, Israel CabezaHu, HuabinMitjavila-Domenech, NuriaLindqvist, AnnikaBaranczewski, PawelCarlsson, Jens
By organisation
Computational Biology and BioinformaticsScience for Life Laboratory, SciLifeLabDepartment of Pharmacy
In the same journal
Science Advances
Pharmacology and Toxicology

Search outside of DiVA

GoogleGoogle Scholar
Total: 476 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 451 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf